4.7 Review

Cancer Risk After Resection of Polypoid Dysplasia in Patients With Longstanding Ulcerative Colitis: A Meta-analysis

Journal

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
Volume 12, Issue 5, Pages 756-764

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.cgh.2013.07.024

Keywords

UC; IBD; Surveillance; Inflammatory Bowel Diseases; Neoplasm; Colonoscopy

Funding

  1. Olympus
  2. Abbott
  3. Asahi-Kasei
  4. Bristol-Myers Squibb
  5. Cosmo Technologies
  6. Coronado Biosciences
  7. Ferring Pharmaceuticals
  8. Genentech
  9. Genzyme Corp
  10. GlaxoSmithKline
  11. Janssen
  12. Lexicon Pharmaceuticals
  13. Merck Research Laboratories
  14. Millennium Pharmaceuticals
  15. Nisshin Kyorin Pharmaceuticals
  16. Novartis
  17. Novo Nordisk
  18. NPS Pharmaceuticals
  19. PDL Biopharma
  20. Pfizer
  21. Procter and Gamble
  22. Santarus
  23. Schering Plough
  24. Shire Pharmaceuticals
  25. Sigmoid Pharma Ltd
  26. Tillotts Pharma AG
  27. TxCell SA
  28. UCB Pharma
  29. Warner Chilcott UK Ltd

Ask authors/readers for more resources

BACKGROUND & AIMS: American and European guidelines propose complete endoscopic resection of polypoid dysplasia (adenomas or adenoma-like masses) in patients with longstanding colitis, with close endoscopic follow-up. The incidence of cancer after detection of flat low-grade dysplasia or dysplasia-associated lesion or mass is estimated at 14 cases/1000 years of patient follow-up. However, the risk for polypoid dysplasia has not been determined with precision. We investigated the risk of cancer after endoscopic resection of polypoid dysplasia in patients with ulcerative colitis. METHODS: MEDLINE, EMBASE, PubMed, and the Cochrane library were searched for studies of patients with colitis and resected polypoid dysplasia, with reports of colonoscopic follow-up and data on cancers detected. Outcomes from included articles were pooled to provide a single combined estimate of outcomes by using Poisson regression. RESULTS: Of 425 articles retrieved, we analyzed data from 10 studies, comprising 376 patients with colitis and polypoid dysplasia with a combined 1704 years of follow-up. A mean of 2.8 colonoscopies were performed for each patient after the index procedure (range, 0-15 colonoscopies). The pooled incidence of cancer was 5.3 cases (95% confidence interval, 2.7-10.1 cases)/1000 years of patient follow-up. There was no evidence of heterogeneity or publication bias. The pooled rate of any dysplasia was 65 cases (95% confidence interval, 54-78 cases)/1000 patient years. CONCLUSION: Patients with colitis have a low risk of colorectal cancer after resection of polypoid dysplasia; these findings support the current strategy of resection and surveillance. However, these patients have a 10-fold greater risk of developing any dysplasia than colorectal cancer and should undergo close endoscopic follow-up.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available